Lilly chooses another Corcept compound to combat Zyprexa weight gain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly will fund studies to test effectiveness of Corcept Therapeutics' cortisol receptor antagonist CORT-108297 in rat models of olanzapine-induced weight gain, Corcept says Sept. 3. Corlux (mifepristone), Corcept's antipsychotic cortisol receptor antagonist also funded in part by Lilly, has reduced and mitigated weight gain associated with olanzapine (Lilly's atypical antipsychotic Zyprexa), but is more commonly known for its anti-progestational abortifacient properties (1Pharmaceutical Approvals Monthly September 2004, p. 14). CORT-108297 does not have Corlux's potent affinity for the PR receptor